메뉴 건너뛰기




Volumn 17, Issue 11, 2015, Pages 1056-1064

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: A randomized, placebo-controlled trial

Author keywords

GLP 1 analogue; Glycaemic control; Incretin therapy; Insulin therapy; Randomised trial; Weight loss therapy

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PLACEBO; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

EID: 84945492252     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12539     Document Type: Article
Times cited : (95)

References (50)
  • 2
    • 84866268783 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    • Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
    • (2012) Diabetes Care , vol.35 , pp. 1364-1379
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 3
    • 0032983666 scopus 로고    scopus 로고
    • Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group
    • Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
    • (1999) JAMA , vol.281 , pp. 2005-2012
    • Turner, R.C.1    Cull, C.A.2    Frighi, V.3    Holman, R.R.4
  • 4
    • 0242269000 scopus 로고    scopus 로고
    • The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
    • Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
    • (2003) Diabetes Care , vol.26 , pp. 3080-3086
    • Riddle, M.C.1    Rosenstock, J.2    Gerich, J.3
  • 5
    • 43849105857 scopus 로고    scopus 로고
    • Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial
    • Weng J, Li Y, Xu W. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371: 1753-1760.
    • (2008) Lancet , vol.371 , pp. 1753-1760
    • Weng, J.1    Li, Y.2    Xu, W.3
  • 6
    • 77954917386 scopus 로고    scopus 로고
    • Addressing barriers to initiation of insulin in patients with type 2 diabetes
    • Peyrot M, Rubin RR, Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes 2010; 4: S11-18.
    • (2010) Prim Care Diabetes , vol.4 , pp. S11-S18
    • Peyrot, M.1    Rubin, R.R.2    Khunti, K.3
  • 7
    • 57649234120 scopus 로고    scopus 로고
    • The incretin system and its role in type 2 diabetes mellitus
    • Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009; 297: 127-136.
    • (2009) Mol Cell Endocrinol , vol.297 , pp. 127-136
    • Holst, J.J.1    Vilsboll, T.2    Deacon, C.F.3
  • 8
    • 84870054636 scopus 로고    scopus 로고
    • GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
    • Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728-742.
    • (2012) Nat Rev Endocrinol , vol.8 , pp. 728-742
    • Meier, J.J.1
  • 9
    • 84908164432 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 receptor agonist or bolus insulin with optimized basal insulin in diabetes
    • Diamant M, Nauck MA, Shaginian R etal. Glucagon-like peptide-1 receptor agonist or bolus insulin with optimized basal insulin in diabetes. Diabetes Care 2014; 37: 2763-2773.
    • (2014) Diabetes Care , vol.37 , pp. 2763-2773
    • Diamant, M.1    Nauck, M.A.2    Shaginian, R.3
  • 10
    • 79551615182 scopus 로고    scopus 로고
    • Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial
    • Buse JB, Bergenstal RM, Glass LC etal. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011; 154: 103-112.
    • (2011) Ann Intern Med , vol.154 , pp. 103-112
    • Buse, J.B.1    Bergenstal, R.M.2    Glass, L.C.3
  • 11
    • 84858079439 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction
    • Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes 2011; 6: 41-46.
    • (2011) Prim Care Diabetes , vol.6 , pp. 41-46
    • Lind, M.1    Jendle, J.2    Torffvit, O.3    Lager, I.4
  • 12
    • 84904977278 scopus 로고    scopus 로고
    • Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro
    • Rosenstock J, Fonseca VA, Gross JL etal. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care 2014; 37: 2317-2325.
    • (2014) Diabetes Care , vol.37 , pp. 2317-2325
    • Rosenstock, J.1    Fonseca, V.A.2    Gross, J.L.3
  • 13
    • 84878592117 scopus 로고    scopus 로고
    • Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)
    • Riddle MC, Aronson R, Home P etal. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013; 36: 2489-2496.
    • (2013) Diabetes Care , vol.36 , pp. 2489-2496
    • Riddle, M.C.1    Aronson, R.2    Home, P.3
  • 14
    • 67650066860 scopus 로고    scopus 로고
    • Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD)
    • Zinman B, Gerich J, Buse J etal. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224-1230.
    • (2009) Diabetes Care , vol.32 , pp. 1224-1230
    • Zinman, B.1    Gerich, J.2    Buse, J.3
  • 15
    • 69949117621 scopus 로고    scopus 로고
    • Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
    • Russell-Jones D, Vaag A, Schmitz O etal. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-2055.
    • (2009) Diabetologia , vol.52 , pp. 2046-2055
    • Russell-Jones, D.1    Vaag, A.2    Schmitz, O.3
  • 16
    • 62449129181 scopus 로고    scopus 로고
    • Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)
    • Marre M, Shaw J, Brandle M etal. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-278.
    • (2009) Diabet Med , vol.26 , pp. 268-278
    • Marre, M.1    Shaw, J.2    Brandle, M.3
  • 17
    • 59449101432 scopus 로고    scopus 로고
    • Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
    • Garber A, Henry R, Ratner R etal. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
    • (2009) Lancet , vol.373 , pp. 473-481
    • Garber, A.1    Henry, R.2    Ratner, R.3
  • 18
    • 67649666737 scopus 로고    scopus 로고
    • Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
    • Buse JB, Rosenstock J, Sesti G etal. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
    • (2009) Lancet , vol.374 , pp. 39-47
    • Buse, J.B.1    Rosenstock, J.2    Sesti, G.3
  • 19
    • 77952309372 scopus 로고    scopus 로고
    • Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
    • Pratley RE, Nauck M, Bailey T etal. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-1456.
    • (2010) Lancet , vol.375 , pp. 1447-1456
    • Pratley, R.E.1    Nauck, M.2    Bailey, T.3
  • 20
    • 62449169287 scopus 로고    scopus 로고
    • Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes
    • Nauck M, Frid A, Hermansen K etal. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care 2009; 32: 84-90.
    • (2009) Diabetes Care , vol.32 , pp. 84-90
    • Nauck, M.1    Frid, A.2    Hermansen, K.3
  • 21
    • 84862903186 scopus 로고    scopus 로고
    • Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets
    • DeVries JH, Bain SC, Rodbard HW etal. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012; 35: 1446-1454.
    • (2012) Diabetes Care , vol.35 , pp. 1446-1454
    • DeVries, J.H.1    Bain, S.C.2    Rodbard, H.W.3
  • 22
    • 84883778164 scopus 로고    scopus 로고
    • One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target
    • Rosenstock J, Rodbard HW, Bain SC etal. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. J Diabetes Complications 2013; 27: 492-500.
    • (2013) J Diabetes Complications , vol.27 , pp. 492-500
    • Rosenstock, J.1    Rodbard, H.W.2    Bain, S.C.3
  • 23
    • 84903121563 scopus 로고    scopus 로고
    • A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)
    • Mathieu C, Rodbard HW, Cariou B etal. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab 2014; 16: 636-644.
    • (2014) Diabetes Obes Metab , vol.16 , pp. 636-644
    • Mathieu, C.1    Rodbard, H.W.2    Cariou, B.3
  • 24
    • 84945460837 scopus 로고    scopus 로고
    • ICH harmonised tripartite guideline: guideline for good clinical practice E6 (R1), step 4. 6.10.
    • International Conference on Harmonisation. ICH harmonised tripartite guideline: guideline for good clinical practice E6 (R1), step 4. 6.10.1996.
    • (1996)
  • 25
    • 0003871544 scopus 로고    scopus 로고
    • World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects
    • Last amended by the 59th WMA General Assembly, Seoul.
    • World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Last amended by the 59th WMA General Assembly, Seoul. 2008.
    • (2008)
  • 26
    • 0032972427 scopus 로고    scopus 로고
    • Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur
    • Bradley C. Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care 1999; 22: 530-532.
    • (1999) Diabetes Care , vol.22 , pp. 530-532
    • Bradley, C.1
  • 27
    • 18144388647 scopus 로고    scopus 로고
    • Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia
    • Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-1249.
    • (2005) Diabetes Care , vol.28 , pp. 1245-1249
  • 28
    • 79952755181 scopus 로고    scopus 로고
    • One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
    • Pratley R, Nauck M, Bailey T etal. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011; 65: 397-407.
    • (2011) Int J Clin Pract , vol.65 , pp. 397-407
    • Pratley, R.1    Nauck, M.2    Bailey, T.3
  • 29
    • 33746391488 scopus 로고    scopus 로고
    • A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes
    • Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.
    • (2006) Diabetes Care , vol.29 , pp. 1269-1274
    • Hermansen, K.1    Davies, M.2    Derezinski, T.3    Martinez, R.G.4    Clauson, P.5    Home, P.6
  • 30
    • 84905580879 scopus 로고    scopus 로고
    • Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)
    • de Wit HM, Vervoort GM, Jansen HJ, de Grauw WJ, de Galan BE, Tack CJ. Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT). Diabetologia 2014; 57: 1812-1819.
    • (2014) Diabetologia , vol.57 , pp. 1812-1819
    • de Wit, H.M.1    Vervoort, G.M.2    Jansen, H.J.3    de Grauw, W.J.4    de Galan, B.E.5    Tack, C.J.6
  • 31
    • 84908177336 scopus 로고    scopus 로고
    • Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
    • Dungan KM, Povedano ST, Forst T etal. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014; 384: 1349-1357.
    • (2014) Lancet , vol.384 , pp. 1349-1357
    • Dungan, K.M.1    Povedano, S.T.2    Forst, T.3
  • 32
    • 84872084453 scopus 로고    scopus 로고
    • Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
    • Buse JB, Nauck M, Forst T etal. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013; 381: 117-124.
    • (2013) Lancet , vol.381 , pp. 117-124
    • Buse, J.B.1    Nauck, M.2    Forst, T.3
  • 33
    • 84899585635 scopus 로고    scopus 로고
    • Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
    • Pratley RE, Nauck MA, Barnett AH etal. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014; 2: 289-297.
    • (2014) Lancet Diabetes Endocrinol , vol.2 , pp. 289-297
    • Pratley, R.E.1    Nauck, M.A.2    Barnett, A.H.3
  • 35
    • 84898800517 scopus 로고    scopus 로고
    • Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus
    • Torekov SS, Holst JJ, Ehlers MR. Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014; 16: 451-456.
    • (2014) Diabetes Obes Metab , vol.16 , pp. 451-456
    • Torekov, S.S.1    Holst, J.J.2    Ehlers, M.R.3
  • 36
    • 84902254986 scopus 로고    scopus 로고
    • Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
    • van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014; 38: 784-793.
    • (2014) Int J Obes (Lond) , vol.38 , pp. 784-793
    • van Can, J.1    Sloth, B.2    Jensen, C.B.3    Flint, A.4    Blaak, E.E.5    Saris, W.H.6
  • 37
    • 84883721678 scopus 로고    scopus 로고
    • The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment
    • Flint A, Kapitza C, Zdravkovic M. The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment. Diabetes Obes Metab 2013; 15: 958-962.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 958-962
    • Flint, A.1    Kapitza, C.2    Zdravkovic, M.3
  • 38
    • 84928926835 scopus 로고    scopus 로고
    • Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss
    • Iepsen EW, Lundgren J, Dirksen C etal. Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss. Int J Obes (Lond) 2015; 39: 834-841.
    • (2015) Int J Obes (Lond) , vol.39 , pp. 834-841
    • Iepsen, E.W.1    Lundgren, J.2    Dirksen, C.3
  • 39
    • 84945450226 scopus 로고    scopus 로고
    • GlaxoSmithKline, UK. Eperzan (albiglutide) [EU summary of product characteristics]. Accessed 6 June 2015.
    • GlaxoSmithKline, UK. Eperzan (albiglutide) [EU summary of product characteristics]. 2014. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002735/WC500165117.pdf. Accessed 6 June 2015.
    • (2014)
  • 40
    • 84945476020 scopus 로고    scopus 로고
    • Eli Lilly and Company, Indianapolis. Trulicity (dulaglutide) [US Package Insert]. Accessed 6 June 2015.
    • Eli Lilly and Company, Indianapolis. Trulicity (dulaglutide) [US Package Insert]. 2014. Available from URL: http://pi.lilly.com/us/trulicity-uspi.pdf. Accessed 6 June 2015.
    • (2014)
  • 41
    • 84945497015 scopus 로고    scopus 로고
    • San Diego. Bydureon (exenatide) [EU summary of product characteristics]. Accessed 6 June 2015.
    • Amylin Pharmaceuticals, Inc., San Diego. Bydureon (exenatide) [EU summary of product characteristics]. 2011. Available from URL: http://www.astrazeneca-us.com/cgi-bin/az_pi.cgi?product=bydureon&country=us&popup=no. Accessed 6 June 2015.
    • (2011)
  • 42
    • 79951702236 scopus 로고    scopus 로고
    • Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database
    • Best JH, Hoogwerf BJ, Herman WH etal. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011; 34: 90-95.
    • (2011) Diabetes Care , vol.34 , pp. 90-95
    • Best, J.H.1    Hoogwerf, B.J.2    Herman, W.H.3
  • 43
    • 84890572455 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials
    • Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014; 16: 38-47.
    • (2014) Diabetes Obes Metab , vol.16 , pp. 38-47
    • Monami, M.1    Dicembrini, I.2    Nardini, C.3    Fiordelli, I.4    Mannucci, E.5
  • 44
    • 79952694840 scopus 로고    scopus 로고
    • Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
    • Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011; 10: 22.
    • (2011) Cardiovasc Diabetol , vol.10 , pp. 22
    • Ratner, R.1    Han, J.2    Nicewarner, D.3    Yushmanova, I.4    Hoogwerf, B.J.5    Shen, L.6
  • 45
    • 84945452870 scopus 로고    scopus 로고
    • Medical review: Dulaglutide (Trulicity).
    • Food and Drug Administration Center for Drug Evaluation and Research (CDER). Medical review: Dulaglutide (Trulicity). 2015.
    • (2015)
  • 46
    • 79952975117 scopus 로고    scopus 로고
    • Surveillance of lipase and amylase levels in type 2 diabetes patients assessed during a randomized clinical study: the EGO study experience
    • Bastyr EJ, Vinik A, Owyang C, Cheng C, Shu J, Hall NC. Surveillance of lipase and amylase levels in type 2 diabetes patients assessed during a randomized clinical study: the EGO study experience. Diabetologia 2009; 52(Suppl. 1): S303-304.
    • (2009) Diabetologia , vol.52 , pp. S303-S304
    • Bastyr, E.J.1    Vinik, A.2    Owyang, C.3    Cheng, C.4    Shu, J.5    Hall, N.C.6
  • 47
    • 84942374717 scopus 로고    scopus 로고
    • Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial
    • Meier JJ, Rosenstock J, Hincelin-Mery A etal. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care 2015; 38: 1263-1673.
    • (2015) Diabetes Care , vol.38 , pp. 1263-1673
    • Meier, J.J.1    Rosenstock, J.2    Hincelin-Mery, A.3
  • 48
    • 84916630493 scopus 로고    scopus 로고
    • LEADER 3-lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER trial
    • Steinberg WM, Nauck MA, Zinman B etal. LEADER 3-lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER trial. Pancreas 2014; 43: 1223-1231.
    • (2014) Pancreas , vol.43 , pp. 1223-1231
    • Steinberg, W.M.1    Nauck, M.A.2    Zinman, B.3
  • 49
    • 84864674632 scopus 로고    scopus 로고
    • Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting
    • Lando HM, Alattar M, Dua AP. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract 2012; 18: 472-477.
    • (2012) Endocr Pract , vol.18 , pp. 472-477
    • Lando, H.M.1    Alattar, M.2    Dua, A.P.3
  • 50
    • 79952284556 scopus 로고    scopus 로고
    • GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide
    • Hegedus L, Moses AC, Zdravkovic M, Le TT, Daniels GH. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011; 96: 853-860.
    • (2011) J Clin Endocrinol Metab , vol.96 , pp. 853-860
    • Hegedus, L.1    Moses, A.C.2    Zdravkovic, M.3    Le, T.T.4    Daniels, G.H.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.